The paper “Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas” published in the European Journal of Cancer is undoubtedly of significance. Curious about the findings, I interviewed Professor Dr. Lars Lindner of Ludwig-Maximilians-Universität (LMU) in Munich. The renowned expert kindly agreed to respond to my questions regarding the various modalities compared in the paper, including CT, regional hyperthermia and immunotherapeutic agents, as well as the implications for the future. We have also produced an infographic that illustrates the long-term results of the EORTC 62961-ESHO 95 trial published in JAMA Oncology (Issels et al., 2018).Summary, Interview, Infographic
ESTRO 2021 (European Society for Radiotherapy and Oncology)
(hybrid) Aug. 27 – 31, 2021
- 25th SASRO Annual Meeting (Scientific Association of Swiss Radiation Oncology) Rorschach, Switzerland Sep. 02 – 03, 2021
- 13th ICHO (International Congress of Hyperthermic Oncology) Rotterdam, Netherlands (virtual) Oct. 06 – 09, 2021
- ÖGRO Jahrestagung 2021 (Austrian Society for Radiation Oncology) Vienna, Austria Oct. 07 – 09, 2021
- Sarkomkonferenz Berlin, Germany Nov. 18 – 20, 2021
BrochuresView All Brochures
The annual award is given in recognition of ESHO members who have served hyperthermia with outstanding merit. Noting the fact that the decision to honor Prof. Datta was unanimous, Prof. van Rhoon summarized his achievements in the field. With his meta-analyses, Prof. Datta provides evidence of the benefits of clinical hyperthermia at the highest level.
Paul Turner, CTO at Pyrexar Medical Corporation covers “Present and Future Hyperthermia Technology Evolution”.
Paul Turner has been developing hyperthermia and ablation heat treatment methods for more than 40 years, including RF phased array systems for deep non-invasive and invasive phased arrays.